Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy

Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, have improved survival of patients with multiple myeloma (MM). However, these therapies are associated with an increased risk of venous thromboembolism (VTE). Apixaban has been approved for treatment of acute VTE...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornell, Robert Frank, Goldhaber, Samuel Z., Engelhardt, Brian G., Moslehi, Javid, Jagasia, Madan, Patton, Daryl, Harrell, Shelton, Hall, Robert, Wyatt, Houston, Piazza, Greg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401636/
https://www.ncbi.nlm.nih.gov/pubmed/30873378
http://dx.doi.org/10.3389/fonc.2019.00045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401636/
https://www.ncbi.nlm.nih.gov/pubmed/30873378
http://dx.doi.org/10.3389/fonc.2019.00045

Ejemplares similares